New data on liquid biopsy for colorectal cancer detection still underwhelms
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we talk about how biopharma plans to harness AI for clinical trial design, why two experts think Medicare ought to cover the costly GLP-1 drugs, and what news from Roivant means for its business strategy.
Read Original Article: New data on liquid biopsy for colorectal cancer detection still underwhelms »
